The Global Health Body Issues Concern Over Severe Scarcity of Weight-Loss Medications
Under one in 10 individuals who could benefit from obesity jabs including Wegovy can access them, states the WHO as it releases its initial guidance on the drugs.
Considering more than one billion people worldwide now obese, it is advocating for more widespread and fairer availability to these injectable treatments.
According to projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a lifelong illness that can be managed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are significant hurdles to universal access to the treatments that can assist patients in reducing substantial body mass, says the body.
GLP-1 Therapy Scarcity
Even in the current best projected outlook, the supply of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, as stated by the WHO.
The advice encourages nations and manufacturers to widen access, via approaches such as patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
How Obesity Injections Function
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, curb appetite and boost the sense of being full so individuals consume fewer calories.
Individuals usually begin shedding pounds in the initial weeks of beginning the regular doses.
Research points to users may see weight return within a year of discontinuing the treatment, because their normal hunger resume.
Being above a healthy weight elevates your chance for experiencing medical conditions, including diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
